Foresite Capital Management II’s Juno Therapeutics, Inc. JUNO Stock Holding History

Foresite Capital Management II’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-85,000	Closed	-$3.88M	–	15
2017 Q4	$3.88M	Sell	85,000 -5,000	-6%	-$249K	1.36%	8
2017 Q3	$4.04M	Buy	+90,000	New	+$3.07M	1.64%	7
2015 Q3	–	Sell	-91,575	Closed	-$4.88M	–	31
2015 Q2	$4.88M	Hold	91,575	–	–	1.71%	14
2015 Q1	$5.55M	Hold	91,575	–	–	3.29%	8
2014 Q4	$4.78M	Buy	+91,575	New	+$4.1M	3.27%	10

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Foresite Capital Management II's JUNO Position: Q1 2018 in Review

Foresite Capital Management II sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 85,000 shares — an estimated $3.88M sold.

Foresite Capital Management II first reported a position in JUNO in Q4 2014 and held it in 5 quarters. The position peaked at $5.55M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Foresite Capital Management II reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Foresite Capital Management II sold 85,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.88M.
Foresite Capital Management II first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
Foresite Capital Management II's Juno Therapeutics, Inc. position peaked at $5.55M in Q1 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Foresite Capital Management II's 13F filing for Q1 2018, filed 15 May 2018.